A phase I study of human natural interferon-beta in cancer patients

J Interferon Res. 1989 Jun;9(3):339-48. doi: 10.1089/jir.1989.9.339.

Abstract

In this phase I study 15 patients with metastatic tumors were given interferon (IFN)-beta by i.v. bolus injections. Twelve individual doses of 1, 2, 3.3, 5, 7, 9, 12, 16, 21, 27, 35, and 46 x 10(6) IU were administered every other day. The single maximal tolerated dose ranged from 9 to 46 x 10(6) IU. Eight patients tolerated the dose of 46 x 10(6) IU without side effects. Disturbances of cardiac rhythm were observed, but were closely related temporally to severe chills and appeared to be the consequence of adrenergic stimulation associated with this side-effect. In addition, no significant variations in the left ventricular function as assessed by nuclear stethoscope were observed. Neurotoxicity was not a major side-effect. The toxicity of IFN-beta given as scheduled in this study was significant, but acceptable.

MeSH terms

  • Adult
  • Aged
  • Arrhythmias, Cardiac / etiology
  • Blood Cell Count
  • Blood Pressure
  • Body Temperature
  • Drug Evaluation
  • Electroencephalography
  • Fever / etiology
  • Heart Diseases / etiology
  • Heart Rate
  • Humans
  • Interferon Type I / pharmacology
  • Interferon Type I / toxicity*
  • Leukopenia / etiology
  • Middle Aged
  • Neoplasms / blood
  • Neoplasms / therapy*
  • Respiratory Function Tests

Substances

  • Interferon Type I